Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

PROs, Gene Expression Vary Among Patients With AML Undergoing Induction Chemo

April 11th 2025

PROs and gene expression in peripheral blood varied in patients with acute myeloid leukemia receiving induction chemotherapy.

Daratumumab Significantly Reduces Progression Risk in High-Risk Smoldering Multiple Myeloma

April 11th 2025

Daratumumab reduced the risk of disease progression or death vs active monitoring in high-risk smoldering multiple myeloma.

Tarlatamab Yields OS Improvement in SCLC After Platinum Progression

April 11th 2025

Tarlatamab improved overall survival vs chemotherapy in small cell lung cancer following progression on or after platinum-based chemotherapy.

Health Canada Approves Durvalumab Monotherapy for Limited-Stage Small Cell Lung Cancer

April 11th 2025

Durvalumab received approval from Health Canada for patients with LS-SCLC whose disease has not progressed after platinum-based chemoradiation.

PSMAfore Data Drive Expanded Approval of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

April 11th 2025

Michael J. Morris, MD, discusses data from the PSMAfore trial that supported the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in mCRPC.

Subcutaneous Nivolumab Sustains Comparable Efficacy, Safety to IV Formulation in Advanced ccRCC

April 10th 2025

Subcutaneous nivolumab demonstrated comparable efficacy, safety, and tolerability to IV nivolumab in advanced clear cell renal cell carcinoma.

Tailored Interventions Are Needed to Reduce Barriers to Breast Cancer Screening in Jordan

April 10th 2025

A study identified individual and non-individual factors as barriers to breast cancer screening for women in Jordan.

FDA Greenlights Bevacizumab Biosimilar in Multiple Solid Tumor Indications

April 10th 2025

The bevacizumab biosimilar Jobevne was approved by the FDA for the treatment of several solid tumor types, including mCRC, NSCLC, and RCC.

FDA Approves Larotrectinib for NTRK-Positive Solid Tumors

April 10th 2025

The FDA has granted full approval to larotrectinib for select patients with solid tumors harboring a NTRK gene fusion.

Expanded FDA Approval Broadens the Role of Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mCRPC

April 9th 2025

Michael J. Morris, MD, discusses the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in PSMA-positive mCRPC.

SON-1010 Plus Atezolizumab Is Safe, Displays Preliminary Efficacy in Platinum-Resistant Ovarian Cancer

April 9th 2025

SON-1010 plus atezolizumab was safe and showed clinical activity in platinum-resistant ovarian cancer and other advanced solid tumors.

Enhanced Bladder Cancer Outcomes Stem From Individualized First-Line Regimens

April 9th 2025

Chandler Park, MD, FACP, discusses optimal clinical scenarios for the use of the 3 approved first-line treatment options for patients with bladder cancer.

Subcutaneous Pembrolizumab Is Noninferior to IV Formulation in Metastatic NSCLC

April 9th 2025

Subcutaneous and intravenous pembrolizumab provided comparable efficacy and safety in patients with previously untreated, metastatic non–small cell lung cancer.

Dr Lenz on the FDA Approval of Nivolumab Plus Ipilimumab for dMMR/MSI-H mCRC

April 8th 2025

Heinz-Josef Lenz, MD, discusses data from the CheckMate 8HW trial that led to the FDA approval of nivolumab plus ipilimumab for dMMR/MSI-H metastatic CRC.

Daraxonrasib Generates Clinical Activity With Manageable Safety in RAS-Mutant NSCLC

April 8th 2025

Daraxonrasib was safe and active in the pretreated advanced non–small cell lung cancer harboring RAS mutations.

FDA Approves Nivolumab Plus Ipilimumab for dMMR/MSI-H Metastatic CRC

April 8th 2025

The FDA has granted approval to nivolumab plus ipilimumab for the treatment of patients with dMMR/MSI-H metastatic colorectal cancer.

Tambiciclib Generates Potential OS Benefit in R/R AML

April 8th 2025

Tambiciclib generated a median overall survival of 8.8 months in patients with relapsed/refractory acute myeloid leukemia.

Dato-DXd Secures EU Approval for Pretreated HR+/HER2– Metastatic Breast Cancer

April 8th 2025

The European Commission approved Dato-DXd for advanced HR-positive, HER2-negative breast cancer after endocrine therapy and chemotherapy.

FDA Approval Is Sought for Ziftomenib in NMP1-Mutant R/R AML

April 8th 2025

The FDA has received an NDA for ziftomenib in relapsed/refractory NMP1-mutant acute myeloid leukemia.

Savolitinib Plus Osimertinib Elicits Durable Responses in Pretreated EGFR-Mutated, MET+ Advanced NSCLC

April 7th 2025

Savolitinib plus osimertinib produced responses in pretreated MET-amplified or -overexpressed advanced non–small cell lung cancer harboring EGFR mutations.